Four Ways Pharmaceutical Companies Are De-Risking R&D with Real-World Data
Four Ways Pharmaceutical Companies Are De-Risking R&D with Real-World Data Pharmaceutical research and development is inherently complex and high-risk. Sponsors must ensure that investigational products demonstrate both strong therapeutic efficacy and an acceptable safety profile. At the same time, they must manage escalating costs, lengthy timelines, and increasing expectations from regulators, payers, and patients. Despite […]
RWD and GenAI: How technology’s new power couple will revolutionize life sciences
Generative AI (GenAI) is quickly proving itself to be one of the most transformative technologies of our time with its ability to synthesize data and create new content as well as (or sometimes better than) its human creators. But GenAI needs a powerful partner if it’s going to wow users with high-quality, trustworthy, bias-free results: […]
Who, what, when…and especially where: Why care settings matter for representative real-world datasets
A vast majority of cancer patients’ care starts with a visit to a primary care provider for a routine screening or consult for a worrisome symptom. They may visit a local hospital or health system for testing and initial review by a specialist – but from there, the care pathway could take several different routes. […]
Introducing CAILIN: The Latest Development from COTA’s AI Lab
At COTA, we know that high-quality oncology real-world data (RWD) holds the keys to the next breakthrough in cancer care. Through our work with life sciences partners, oncologists, and hospitals across the U.S., we’ve seen firsthand how data can power discoveries about new treatments and inform the right steps in care for patients. We also […]
